A pharmaceutical cooperation project is often introduced with one of three labels: CMO, CDMO or technology transfer. These terms are useful commercial shorthand, but they are not a complete scope of work. A reliable selection starts by defining the product's maturity, the missing evidence, the target market, the responsibilities of each party and the intended end state.
1. Begin with the operating question, not the acronym
The first question should not be “Which label do we prefer?” It should be: What must be true at the end of this project? The answer might be routine manufacture of an already established product at a contract site; completion of development and scale-up before commercial supply; or establishment of repeatable manufacture and testing at a receiving site.
FDA's quality-agreement guidance explains that parties in contract drug manufacturing can use a written quality agreement to define and document their manufacturing activities and CGMP responsibilities. ICH Q10 extends pharmaceutical quality-system thinking across development, technology transfer and commercial manufacturing, including control of outsourced activities. These sources do not create a universal commercial definition of “CMO” or “CDMO”; they reinforce why the actual activities, decision rights and evidence requirements matter more than the label. [1] [2]
2. Distinguish the three starting models
| Model | Typical starting point | Primary work | Typical end state |
|---|---|---|---|
| CMO | A relatively mature product, process and test package | Transfer, site fit, validation, routine manufacture, testing and supply under agreed responsibilities | Commercial manufacture at the contract site |
| CDMO | Material development or evidence gaps remain | Formulation, process or analytical development; scale-up; transfer; validation; agreed registration support; manufacture | A development package and a commercially executable process within the agreed scope |
| Technology transfer | A product, process or analytical procedure is to be reproduced at a receiving unit | Knowledge transfer, gap assessment, training, method/process transfer, engineering work, validation and acceptance | The receiving unit can routinely reproduce the agreed product, process or procedure in a controlled state |
These models can be combined. A CDMO engagement may mature into long-term contract manufacturing. A technology-transfer program may include development work if the receiving site exposes gaps. Conversely, a project described as CMO may need to be re-scoped if the dossier, methods or process are not sufficiently mature.
3. Use five questions to select the starting model
- How mature is the product and process? Confirm whether formulation, manufacturing process, container-closure system, specifications, analytical procedures and critical controls are established. A product that still requires material formulation or process decisions normally needs more than a manufacturing-only scope.
- Is the evidence package transferable? Identify development reports, process knowledge, method validation, stability, batch history, deviations and regulatory commitments. “Commercially supplied” does not automatically mean the package is complete or transferable to a different site.
- Which market is targeted, and who owns the regulatory pathway? Define the applicant or authorization holder, submission responsibilities, approved or proposed dossier, site-change implications, local testing, inspection readiness and post-approval changes. Registration support must be described as specific deliverables, not a general promise.
- Where should routine capability reside at the end? If the contract site will manufacture for the long term, a CMO/CDMO operating model may be central. If a local or partner site must ultimately own routine execution, the program should be designed as technology transfer with a defined sending unit, receiving unit and acceptance strategy.
- What schedule, governance and supply model are realistic? Align batches, equipment, materials, analytical capacity, validation, quality agreement, decision gates, release pathway, forecast, inventory and continuity arrangements. An aggressive date cannot substitute for missing product knowledge or regulatory clarity.
4. Apply a simple decision route
If yes, begin with a CDMO-style scope that identifies each development deliverable and acceptance criterion.
If yes, evaluate a CMO scope, while still confirming transfer, validation, regulatory and quality responsibilities.
If yes, structure a technology-transfer program, whether or not development and contract manufacture are also included.
Use a phased hybrid: development → transfer and validation → commercial manufacture → optional transfer to a final receiving unit.
5. Define the scope through responsibility and evidence
Before commercial quotation or scheduling becomes binding, the parties should create a responsibility matrix covering development, technology transfer, materials, methods, validation, stability, batch documentation, release support, deviations, change control, complaints, regulatory communication, intellectual property and data governance. FDA's guidance is particularly clear that a quality agreement should describe the respective CGMP-related activities and does not remove either party's applicable responsibilities. [1]
WHO describes pharmaceutical technology transfer as a planned process involving a sending unit and receiving unit, supported by trained personnel, a quality system, appropriate documentation, gap analysis and agreed evidence that the receiving unit can reproduce the transferred work. [3] ICH Q9(R1) adds an important discipline: the level of formality and effort in risk management should be commensurate with uncertainty, importance and complexity. [4]
6. Watch for the signals that a label is hiding a gap
- The project is called CMO, but the formulation, process parameters or methods are still changing.
- The project is called CDMO, but the required development studies and decision criteria are not listed.
- The project is called technology transfer, but no sending unit, receiving unit, gap assessment or acceptance protocol exists.
- “Regulatory support” is promised without identifying the market, applicant, dossier owner or deliverables.
- Commercial timing is discussed before facility fit, analytical readiness, materials and quality governance are understood.
These signals do not automatically make a project unworkable. They indicate that the first deliverable should be a structured feasibility and scope-definition phase.
7. What to provide for a preliminary assessment
A useful initial submission contains only non-confidential facts: dosage form, intended use category, target market, project stage, current manufacturing status, expected presentation and batch scale, preferred cooperation model, desired timing and a short description of the objective. This is enough to decide which experts should review the opportunity and which questions belong in a controlled due-diligence phase.
Frequently asked questions
Can one project include CMO, CDMO and technology transfer?
Yes. The models can be sequential or combined. The contract and quality documentation should separate each phase, deliverable, decision gate and responsibility.
Does a mature product automatically qualify for CMO?
No. The product still requires site-specific technical, analytical, regulatory, quality and supply-chain assessment. A mature product may also reveal transfer gaps.
When should confidential technical information be shared?
Only after initial non-confidential fit is established and the parties have agreed an NDA, permitted use, access controls and a structured review plan.
Who remains responsible for product quality in outsourced manufacture?
Applicable responsibilities depend on the role and jurisdiction. A quality agreement clarifies activities but does not eliminate statutory or regulatory responsibilities. The responsible parties should confirm the market-specific position.
Authoritative sources
This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.